Complying with article 39 of TRIPS... a myth or evolving reality?

Prabuddha Ganguli

World Patent Information, 2003, vol. 25, issue 4, 329-333

Abstract: In the lengthy process for a new pharmaceutical material to progress from innovation to marketplace, the crucial step of gaining statutory authorisation to offer the product to the public involves the creation of large volumes of data. This article explores the way in which this data is, could, or should be protected. Aspects covered include the relevant articles of TRIPS (39 and 70.9), and the protection potentially provided by official secrets acts, trade secrets and confidentiality provisions and exclusive marketing rights. The article concludes with a tabulated summary of the relevant legislation, and term of protection provided, in over 60 countries worldwide.

Keywords: Pharmaceutical; inventions; Statutory; authorisation; Proprietary; data; Data; protection; TRIPS; Official; secrets; acts; Trade; secrets; Confidentiality; provisions; Exclusive; marketing; rights; Worldwide; legislation (search for similar items in EconPapers)
Date: 2003
References: Add references at CitEc
Citations:

Downloads: (external link)
http://www.sciencedirect.com/science/article/pii/S0172-2190(03)00078-4
Full text for ScienceDirect subscribers only

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:eee:worpat:v:25:y:2003:i:4:p:329-333

Ordering information: This journal article can be ordered from
http://www.elsevier.com/wps/find/supportfaq.cws_home/regional
http://www.elsevier. ... _01_ooc_1&version=01

Access Statistics for this article

World Patent Information is currently edited by Michael Blackman

More articles in World Patent Information from Elsevier
Bibliographic data for series maintained by Catherine Liu ().